Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?

REFERENCES

• Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9(9):543–58.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–9.
   PubMed Web of Science ®Google Scholar
• Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;42:70–2.
   Google Scholar
• Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev. 2003;16(4):647–57.
   PubMed Web of Science ®Google Scholar
• Center for International Blood and Marrow Transplant Research (CIBMTR); National Marrow Donor Program (NMDP); European Blood and Marrow Transplant Group (EBMT); American Society of Blood and Marrow Transplantation (ASBMT); Canadian Blood and Marrow Transplant Group (CBMTG); Infectious Disease Society of America (IDSA); Society for Healthcare Epidemiology of America (SHEA); Association of Medical Microbiology and Infectious Diseases Canada (AMMI); Centers for Disease Control and Prevention (CDC). Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44(8):453–558.
   Web of Science ®Google Scholar
• Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, et al.. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:851–6.
   PubMed Web of Science ®Google Scholar
• Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, et al.. Oral valganciclovir as preemptive therapy for cytomegalovirus infection postallogeneic stem cell transplantation. Transpl Infect Dis. 2007;9:102–7.
   PubMed Web of Science ®Google Scholar
• Takenaka K, Eto T, Nagafuji K, Kamezaki K, Matsuo Y, Yoshimoto G, et al.. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol. 2009;89(2):231–7.
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;65:859–78.
   PubMed Web of Science ®Google Scholar
• Devergie A. Graft versus host disease. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, eiditors. Hematopoietic stem cell transplantation. The EBMT handbook, 5th edn. Paris, France: European School of Haematology; 2008. p. 219–35.
   Google Scholar
• Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–7.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151–69
   PubMed Web of Science ®Google Scholar
• Common Toxicity Criteria (CTC). CTC Version 2.0. Publish date: 1999 Apr 30 [document on the Internet]. [cited 2011 Feb 2]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf
   Google Scholar
• Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al.. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.
   PubMed Web of Science ®Google Scholar
• Vander Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. Oral valganciclovir as pre-emptive Therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant. 2006;37:693–8.
   PubMed Web of Science ®Google Scholar
• Palladino M, Laurenti L, Chiusolo P, Piccioni P, Innocenti I, Tarnani M, et al.. Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients. Acta Haematol. 2010;123(4):230–4.
   PubMed Web of Science ®Google Scholar
• Candoni A, Simeone E, Tiribelli M, Pipan C, Fanin R. What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT? Bone Marrow Transplant. 2008;42:207–8.
   PubMed Web of Science ®Google Scholar
• Takenaka K, Nagafuji K, Takase K, Kamimura T, Mori Y, Ito Y, et al.. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol. 2012;96(1):94–100.
   PubMed Web of Science ®Google Scholar
• Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37(2):167–76.
   PubMed Web of Science ®Google Scholar
• Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother. 2009;63(3):600–8.
   PubMed Web of Science ®Google Scholar
• Boutolleau D, Deback C, Bressollette-Bodin C, Varnous S, Dhedin N, Barrou B, et al.. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res. 2009;81(2):174–9.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Baden LR, Gabriel DA, Emmanouilides C, Shaw LM, Lange WR, et al.. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant. 2006;12(6):635–40.
   PubMed Web of Science ®Google Scholar
• Einsele H, Reusser P, Bornhäuser M, Kalhs P, Ehninger G, Hebart H, et al.. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovirin patients following allogeneic stem cell transplantation. Blood. 2006;107:3002–8.
   PubMed Web of Science ®Google Scholar
• Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, et al.. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601–7.
   PubMed Web of Science ®Google Scholar
• Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005–11.
   PubMed Web of Science ®Google Scholar